These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 27153440)

  • 21. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
    Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
    Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
    Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
    Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
    Li S; Zhang W; Chen B; Jiang T; Wang Z
    Neurol Res; 2010 Sep; 32(7):690-4. PubMed ID: 19703338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.
    Lattanzio L; Borgognone M; Mocellini C; Giordano F; Favata E; Fasano G; Vivenza D; Monteverde M; Tonissi F; Ghiglia A; Fillini C; Bernucci C; Merlano M; Lo Nigro C
    Int J Biol Markers; 2015 May; 30(2):e208-16. PubMed ID: 25588856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High IFIT1 expression predicts improved clinical outcome, and IFIT1 along with MGMT more accurately predicts prognosis in newly diagnosed glioblastoma.
    Zhang JF; Chen Y; Lin GS; Zhang JD; Tang WL; Huang JH; Chen JS; Wang XF; Lin ZX
    Hum Pathol; 2016 Jun; 52():136-44. PubMed ID: 26980050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
    Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
    Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.
    Dahlrot RH; Larsen P; Boldt HB; Kreutzfeldt MS; Hansen S; Hjelmborg JB; Kristensen BW
    J Neuropathol Exp Neurol; 2019 Jul; 78(7):633-640. PubMed ID: 31058280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.
    Trabelsi S; Mama N; Ladib M; Karmeni N; Haddaji Mastouri M; Chourabi M; Mokni M; Tlili K; Krifa H; Yacoubi MT; Saad A; H'mida Ben Brahim D
    Clin Transl Oncol; 2016 Apr; 18(4):391-7. PubMed ID: 26289551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
    Tzaridis T; Schäfer N; Weller J; Steinbach JP; Schlegel U; Seidel S; Sabel M; Hau P; Seidel C; Krex D; Goldbrunner R; Tonn JC; Grauer O; Kebir S; Schneider M; Schaub C; Vatter H; Coch C; Glas M; Fimmers R; Pietsch T; Reifenberger G; Herrlinger U; Felsberg J
    Int J Cancer; 2021 Apr; 148(7):1695-1707. PubMed ID: 33113214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
    Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
    Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From
    Qian J; Herman MG; Brinkmann DH; Laack NN; Kemp BJ; Hunt CH; Lowe V; Pafundi DH
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1339-1346. PubMed ID: 32634544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
    Ellingson BM; Cloughesy TF; Pope WB; Zaw TM; Phillips H; Lalezari S; Nghiemphu PL; Ibrahim H; Naeini KM; Harris RJ; Lai A
    Neuroimage; 2012 Jan; 59(2):908-16. PubMed ID: 22001163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.
    Villani V; Casini B; Pace A; Prosperini L; Carapella CM; Vidiri A; Fabi A; Carosi M
    Dis Markers; 2015; 2015():604719. PubMed ID: 26347581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
    Malley DS; Hamoudi RA; Kocialkowski S; Pearson DM; Collins VP; Ichimura K
    Acta Neuropathol; 2011 May; 121(5):651-61. PubMed ID: 21287394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma.
    Kanas VG; Zacharaki EI; Thomas GA; Zinn PO; Megalooikonomou V; Colen RR
    Comput Methods Programs Biomed; 2017 Mar; 140():249-257. PubMed ID: 28254081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.
    Christmann M; Nagel G; Horn S; Krahn U; Wiewrodt D; Sommer C; Kaina B
    Int J Cancer; 2010 Nov; 127(9):2106-18. PubMed ID: 20131314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.